September 15, 2008 - Newport Beach, CA:
Hoag Hospital is the only hospital in Southern California and one of
only 11 test sites in the United States selected to participate in a
multi-center clinical trial studying digital tomosynthesis.
Digital tomosynthesis is a 3D imaging modality, which captures
approximately 11 digital "projection" images from various angles over
the breast, during a short scan, much like a CT scan. These images are
then reconstructed into a series of high resolution 1mm slices that can
be reviewed individually or played back in a cine loop. This provides a
3D view of the breast, potentially alleviating one of the major
limitations of 2D mammography. In traditional mammography, only two 2D
images of the whole breast are obtained, which can be harder to
interpret due to tissue overlap. This limitation leads to the potential
for tumors to be hidden by overlying normal breast tissue.
“In this FDA trial, our goal is to compare and contrast the value of
digital tomosynthesis to that of standard 2D digital mammography,” says
Gary Levine, M.D., director of breast imaging at Hoag Breast Care
Center and lead clinical researcher. “We are investigating this new
technology, as it may prove to be a valuable tool in the early
diagnosis of breast disease.”
During the initial clinical trial period, Hoag Breast Care Center
will only employ the digital tomosynthesis system to screen women and
to image patients who have had suspicious lesions identified with 2D
mammography and who are scheduled for biopsy. The tomosynthesis system
is a 2D/3D unit, which means it can switch between digital
two-dimensional mammogram mode and the three-dimensional digital
tomosynthesis mode to compare results side-by-side. The data from this
study will be compiled by Hologic, developer of the technology, and
sent to the Food and Drug Administration (FDA) as part of the
submission for tomosynthesis approval.
For more information about the tomosynthesis clinical trial at Hoag, please call Hoag Breast Care Center at 949/764-5454 or click here.